Anlon Healthcare Q2 Revenue Rises 15.9% in FY27 Update

Anlon Healthcare Limited reported Q2 revenue of ₹605 million, compared with ₹522 million in the corresponding quarter a year earlier. The 15.90% year-on-year increase points to continued top-line growth in the company’s active pharmaceutical ingredients and drug intermediates business. The update also reported EBITDA of ₹145 million and an EBITDA margin of 23.94%. Net profit was stated at ₹81 million for the quarter, with the update describing profit as lower, although it did not provide a comparable profit figure for that statement. The company is scheduled to discuss its Q2 and first-half FY27 operating and financial performance with investors on November 3, 2026.

Q2 revenue rises from the year-ago quarter

Revenue increased by ₹83 million from ₹522 million in Q2 of the prior year to ₹605 million in Q2 FY27. The disclosed growth rate of 15.90% reflects a steady expansion in the company’s reported sales base. Anlon Healthcare attributed the improvement to demand across its active pharmaceutical ingredients and drug intermediates operations. These business lines supply inputs used in pharmaceutical manufacturing, making volumes, product mix and customer demand relevant to quarterly revenue trends. The available update does not provide a product-wise or customer-wise split of Q2 sales. It also does not specify the geographic source of revenue growth.

Key reported financial metrics

The quarterly figures provide a view of the company’s revenue scale and operating profitability, though the detailed unaudited financial statements were scheduled for board consideration on October 29, 2026. EBITDA of ₹145 million represented 23.94% of reported revenue. The Q2 update placed net profit at ₹81 million. Since a directly comparable Q2 net-profit figure was not included in the supplied information, the precise year-on-year movement in quarterly profit cannot be calculated from the disclosed data. Investors will be able to assess expense trends and other income more fully after the detailed results and management call.

Demand in APIs and intermediates supports sales

The company identified demand in active pharmaceutical ingredients, or APIs, and drug intermediates as the driver of the year-on-year revenue increase. APIs are the components in medicines that produce the intended therapeutic effect, while intermediates are materials used in the manufacture of APIs and other pharmaceutical products. Revenue movement in these categories can be influenced by order schedules, customer inventory decisions, production capacity and product mix. The supplied update does not quantify the contribution of individual products or segments. It therefore remains unclear whether growth was broad-based across the portfolio or concentrated in specific products.

Profitability remains an important focus

The EBITDA margin of 23.94% is an important operating measure because it shows earnings before interest, tax, depreciation and amortisation as a share of revenue. At ₹145 million, reported EBITDA was higher than the stated net profit of ₹81 million, as expected after accounting for items below the operating-profit line. The Q2 update said net profit declined but did not state whether that comparison was year on year or quarter on quarter. It also did not set out the expenses or other factors behind that movement. Further disclosures may clarify the role of raw-material costs, employee expenses, finance costs, depreciation and tax in the quarterly result.

Q1 FY27 provides recent context

Anlon Healthcare had previously reported Q1 FY27 revenue of ₹876.2 million, up 163% from the first quarter of FY26. Another disclosed Q1 comparison said revenue increased 72.06% sequentially from ₹508.9 million. The Q1 earnings release reported net income of ₹66.6 million and a profit margin of 7.6%, down from 11% in Q1 FY26 because of higher expenses. Separately, supplied Q1 summary data listed net profit at ₹82.8 million, indicating differences among the available summaries. The company’s detailed statutory disclosures and the upcoming management discussion will be more relevant sources for reconciling reported profit metrics.

FY26 results show a larger revenue base

For the full year FY26, Anlon Healthcare reported revenue of ₹1,720 million, up 43% from FY25. Net income for FY26 was ₹285.1 million, an increase of 39%, while the profit margin was reported at 17%, in line with the preceding financial year. Earnings per share for FY26 stood at ₹6.11, compared with ₹0.64 in FY25. These figures show that the company entered FY27 after a year of reported revenue and profit expansion. However, quarterly performance can vary due to the timing of deliveries, operating expenses and product mix.

Board meeting and investor call schedule

The company informed exchanges that its board would meet on October 29, 2026, to consider and approve unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. Anlon Healthcare also announced an earnings conference call for November 3, 2026, at 5:00 PM. The call is intended to cover operational and financial performance for Q2 and H1 FY27. Such calls generally provide management’s perspective on reported numbers and enable discussion of operational developments. No guidance or forward-looking financial targets were included in the supplied announcement.

What the update means for investors

The Q2 result confirms that revenue was above the year-ago level, supported by the company’s core pharmaceutical-input operations. The reported EBITDA margin gives investors an initial measure of operating profitability alongside the sales increase. At the same time, the stated decline in net profit highlights the need to review the detailed cost and profit-and-loss disclosures. The lack of a comparable Q2 profit number in the available update limits conclusions about earnings growth. Investors will also watch for any clarification on the difference between the Q1 profit figures appearing in the supplied data.

Next disclosures will add detail

Anlon Healthcare’s Q2 revenue of ₹605 million marks a 15.90% increase from the corresponding prior-year quarter. The result places attention on the company’s API and drug-intermediate demand, operating margin and reported profit movement. Detailed unaudited results for the September quarter and first half are expected to provide a clearer view of costs, segment performance and standalone versus consolidated figures. Management’s November 3, 2026 conference call is the next scheduled event for additional commentary on Q2 and H1 FY27 performance.